Glancy Binkow & Goldberg LLP Announces Investigation of Synovis Life Technologies, Inc.

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of Synovis Life Technologies, Inc. (“Synovis” or the “Company”) (NASDAQ: SYNO) related to the proposed acquisition of the Company by Baxter International, Inc. The transaction is valued at approximately $325 million or $28 per share.

The investigation concerns whether the Board of Directors of Synovis breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. It’s share price has sky rocketed from $14.99 on January 31, 2011 to $21.19 on April 5, 2011.

If you are a shareholder of Synovis, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at [phone] or Toll Free at [phone] or by email to [e-mail].

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.